tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

RedHill Biopharma terminates license agreement for Aemcolo

RedHill Biopharma announced the mutual decision with Cosmo Technologies to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler’s diarrhea. The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024. Per the terms of the License Agreement, RedHill will immediately cease any Aemcolo commercialization of Aemcolo upon termination of the License Agreement, at which point all rights previously ascribed in the License Agreement to RedHill will revert to Cosmo.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1